Background: Rapid, simple, and accurate laboratory detection of carbapenemases is very important for proper antibiotic therapy and infection control.

Methods: In this study, carbapenem-nonsusceptible Enterobacteriaceae (CRE) isolates were used to evaluate the performance of a new lateral flow immunochromatographic (IC) assay, the OXA-48 and KPC K-SeT assay, and modified Blue-Carba test (BCT) for the rapid detection of OXA-48 carbapenemase in comparison with polymerase chain reaction (PCR) amplification. These CREs of various enterobacterial species were isolated from various clinical samples including OXA-48 (47), NDM-1 (6), KPC-1 (1), IMP-1 (1), VIM-2,-4 (2), IMP-2 (1), OXA-51 (1), and OXA-23 (1) producers.

Results: The OXA-48 K-SeT test detected all OXA-48 carbapenemase producers with 100% sensitivity and specificity. The BCT detected carbapenemase producers with 93% sensitivity and 100% specificity.

Conclusions: Both IC assays and BCT tests have good performance and are easy to perform, rapid, simple to interpret, and highly sensitive. We suggest that BCT can be used initially as an accurate, inexpensive, and rapid phenotypic confirmation test to identify Class A, B, and D carbapenemases in the routine diagnostic microbiology laboratory, thus allowing the detection of carbapenemase activity directly from bacterial cultures.

Download full-text PDF

Source
http://dx.doi.org/10.7754/Clin.Lab.2016.160911DOI Listing

Publication Analysis

Top Keywords

oxa-48 kpc
8
kpc k-set
8
k-set assay
8
blue-carba test
8
rapid simple
8
oxa-48 carbapenemase
8
carbapenemase producers
8
oxa-48
6
comparison novel
4
novel oxa-48
4

Similar Publications

Background: This study aimed to explore the distribution of beta-lactamase genes in Enterobacteriaceae from human clinical samples.

Methods: We analyzed data from 83 countries through the Antimicrobial Testing Leadership and Surveillance program, spanning 2004 to 2021. We calculated the proportion of each β-lactamase gene across nine bacterial species and generated a heatmap for β-lactamase genes with a frequency of ≥ 1 % in at least one species.

View Article and Find Full Text PDF

Background and objectives Antimicrobial resistance (AMR) is a growing global threat, with carbapenemase-producing Enterobacterales (CPEs) representing a critical public health challenge. Rapid and accurate detection of CPEs is essential for controlling fatal bacterial AMR infections. This study evaluated the performance of MacConkey media supplemented with ertapenem (MacErt1 and MacErt2) for the detection of CPEs.

View Article and Find Full Text PDF

Rapid antimicrobial susceptibility testing of positive blood cultures can enhance antimicrobial stewardship and patient outcomes. We present a case where OXA-48-producing Klebsiella pneumoniae with low-level carbapenem resistance was suspected 6 h after blood-culture positivity, based on ASTar system (Q-Linea, Sweden) results. OXA-48 carbapenemase presence was confirmed by the OXA-48 K-SeT lateral flow assay (Coris, Belgium) on a short-term subculture.

View Article and Find Full Text PDF

Epidemiological and genetic characteristics of clinical carbapenemase-producing Enterobacterales isolates from Batna hospitals in Algeria.

BMC Infect Dis

December 2024

Laboratoire de Biotechnologie des Molécules Bioactives et de la Physiopathologie Cellulaire (LBMBPC), Faculté des sciences de la Nature et de la vie, Université Batna 2, Batna, Algérie.

Background: Carbapenemase-producing Enterobacterales isolates are associated with significant mortality and have emerged as a major problem in healthcare settings worldwide.

Objective: Our aim was to investigate the epidemiological and genotypic characteristics of carbapenemase-positive Enterobacterales isolates from patients hospitalised in three hospitals in the city of Batna, Algeria.

Methods: Between 2016 and 2019, a total of 5,316 clinical isolates were obtained.

View Article and Find Full Text PDF

Treatment options are limited for infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKP) isolates due to the production of metallo-β-lactamase (MBL). The ceftazidime-avibactam (CZA)/ aztreonam (ATM) combination represents a new therapeutic approach in MBL-positive isolates. Our study aims to determine distribution of carbapenemase genes in CRKP isolates and to investigate the in vitro synergistic effect of the CZA/ATM combination.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!